Mod­er­na CEO Ban­cel ac­knowl­edges a set­back, but stays fo­cused on an up­beat as­sess­ment of 2019

Over much of the past year Mod­er­na $MR­NA has oc­ca­sion­al­ly spot­light­ed its Phase I/II study for methyl­malonic acidemia, which plays a sig­nif­i­cant role in their plans to build a pipeline of mes­sen­ger RNA drugs for rare dis­eases.

The biotech says that on­ly or­gan trans­plants are now avail­able to treat MMA, leav­ing mR­NA-3704 as a crit­i­cal new ther­a­py that could save the lives of chil­dren who suf­fer from the ail­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER